Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Smoldering Multiple Myeloma (19 minutes)
  • CME

Credits Available
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: June 23, 2020 Expiration: June 22, 2021
Start Activity
Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AbbVie
Amgen
Celgene Corporation
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Oncopeptides
Peter M. Voorhees, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan management of patients based on an accurate diagnosis of monoclonal gammopathy of undetermined significance, smoldering MM, or active MM
  • Create individualized treatment strategies for patients with newly diagnosed MM through consideration of the available clinical data as well as risk assessment, age, comorbidities, and patient preferences
  • Evaluate the efficacy and safety evidence of combination regimens to individualize therapeutic strategies for patients with MM at first relapse
  • Plan appropriate treatment strategies using all available agents and classes to provide efficacious combination therapies to heavily pretreated patients with relapsed/refractory MM
  • Employ novel agents and clinical trial participation as part of clinical care strategies for MM

Information on this Educational Activity

Faculty

Peter M. Voorhees, MD

Director, Medical Operations and Outreach Services
Department of Hematology/Oncology
Levine Cancer Institute
Charlotte, North Carolina

Peter M. Voorhees, MD, has no relevant conflicts of interest to report.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has reported that his spouse/partner has ownership interest (stock) in AstraZeneca.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Target Audience

This program is intended for physicians, oncology nurses, pharmacists, and other healthcare providers who care for patients with MM and also patients with MM.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the care of their patients with myeloma.

Physician Continuing Medical Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 23, 2020, through June 22, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Smoldering Multiple Myeloma (19 minutes)
  • CME

Expert discussion of risk stratification for patients with smoldering myeloma and new data on initial management options for patients with high-risk smoldering multiple myeloma.
Peter M. Voorhees, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: June 23, 2020 Expiration: June 22, 2021

This program is divided into several short segments which you can step through using the Video Chapters widget.
PreviousNext

Related Content

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for ALL

Renier J. Brentjens, MD, PhD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

Frederick L. Locke, MD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on emerging CAR T-cell strategies for myeloma.

Noopur Raje, MD Released: December 3, 2020

Downloadable slides on most current clinical data on frontline therapies for CLL.

Jeremy S. Abramson, MD, MMSc Released: December 3, 2020

Video Chapters


Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AbbVie
Amgen
Celgene Corporation
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Oncopeptides

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue